<DOC>
	<DOCNO>NCT01324232</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , efficacy 3 dose AVP-923 capsule treatment central neuropathic pain patient multiple sclerosis .</brief_summary>
	<brief_title>Safety Efficacy AVP-923 Treatment Central Neuropathic Pain Multiple Sclerosis</brief_title>
	<detailed_description>The objective study evaluate safety , tolerability , efficacy 3 dos AVP-923 ( dextromethorphan [ DM ] /quinidine [ Q ] ) capsule contain either 45 mg DM 10 mg Q ( AVP-923-45 ) 30 mg DM 10 mg Q ( AVP-923-30 ) 20 mg DM 10 mg Q ( AVP-923-20 ) compare placebo , treatment central neuropathic pain population patient multiple sclerosis ( MS ) 12-week period . The MS patient population enrol include patient relapsing-remitting multiple sclerosis ( RRMS ) patient secondary progressive multiple sclerosis ( SPMS ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<criteria>Main Multiple Sclerosis ( RRMS SPMS ) , Clinical history symptom central neuropathic pain ( dysesthetic pain ) least 3 month prior screen , PRS baseline score = &gt; 4 , No MS relapse within previous 30 day . Main Personal history complete heart block , QTc prolongation , torsades de pointes , family history congenital QT interval prolongation syndrome , Myasthenia Gravis , BDI score &gt; 19</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>